AllSci News
BeOne Medicines launches ADAM9-targeted ADC into first-in-human study
BeOne Medicines, the global oncology company formerly known as BeiGene, has registered a clinical trial for BG-C0979, the first ADAM9-targeted antibody-drug conjugate…
Compass Pathways plots approval course for psilocybin drug after successful pivotal study
UK-based Compass Pathways announced positive topline results from its second pivotal Phase III clinical trial evaluating COMP360, a proprietary crystalline formulation of…
GSK posts real-world data for Arexvy’s long-term outcomes impact
GSK announced positive real-world evidence from a large-scale observational study evaluating Arexvy (respiratory syncytial virus vaccine, adjuvanted) in adults aged 60 years…
GSK turns to JAX-NYSCF for 5-year collaboration on neurodegenerative diseases
The Jackson Laboratory–New York Stem Cell Foundation Collaborative (JAX-NYSCF) and GSK plc (LSE: GSK) have entered a five-year strategic research collaboration aimed…
Wegovy picks up EC approval for higher dosage
The European Commission (EC) has granted marketing authorization to Novo Nordisk for a new, higher dosage of Wegovy (semaglutide) for the treatment…
Ocular’s Axpaxli becomes first novel agent to beat anti-VEGF standard in wet AMD trial
Massachusetts-based Ocular Therapeutix announced positive topline results from the SOL-1 Phase III superiority trial of Axpaxli (OTX-TKI), an investigational bioresorbable intravitreal hydrogel…
Gilead in-licenses a second synthetic lethality candidate, from China’s Genhouse
Gilead Sciences, Inc., headquartered in Foster City, US, signed an exclusive global license agreement with Genhouse Bio Co., Ltd., based in Suzhou,…
Novartis set to expand Vanrafia to IgA nephropathy after strong Phase III
Novartis announced positive results from the Phase III APPLAUSE-IgAN clinical trial evaluating Vanrafia (iptacopan) in patients with IgA nephropathy (IgAN). Vanrafia is…
HanchorBio’s SIRPα fusion protein takes FDA orphan status in gastric cancer
HanchorBio, Inc. (TPEx: 7827), a clinical-stage biotechnology company headquartered in Taipei, Shanghai, and San Francisco, announced that the US FDA has granted…
Coherus Oncology moving towards public offering to support Loqtorzi commercialization
Redwood City, California-based Coherus Oncology, Inc. (Nasdaq: CHRS) announced a proposed underwritten public offering of its common stock on February 12, 2026.…
PTC calls time on FDA filing for Duchenne’s
PTC Therapeutics, headquartered in Warren, New Jersey, issued notice that its New Drug Application (NDA) with the US FDA for Translarna (ataluren)…
Nxera Pharma licenses GPCR-targeted program to new co.
Nxera Pharma Co., Ltd. announced a GPCR licensing agreement with a newly established independent company created in partnership with a consortium of…
Novo Holdings joins European Life Sciences Coalition to tackle EU funding gap
Novo Holdings, the controlling shareholder in Denmark’s Novo Nordisk, announced its participation in the founding of the newly formed European Life Sciences…
Pfizer halts Phase I trial of Nxera-licensed MC4R antagonist in malnutrition research
Pfizer has terminated a Phase I clinical trial evaluating PF-07258669, an experimental drug targeting unintended weight loss in older adults, according to…
Nektar Therapeutics raises USD 400m in landmark public offering
Nektar Therapeutics (Nasdaq: NKTR), a San Francisco-based clinical-stage biotechnology company, announced a USD 400 million public offering on February 11, 2026. The…
The AllSci Brief
Free, systematic R&D and deal news. Daily.